Bobae Kim - 18 May 2023 Form 4 Insider Report for Bellerophon Therapeutics, Inc. (BLPH)

Role
VP Reg. Affairs & Quality
Signature
/s/ Bobae Kim
Issuer symbol
BLPH
Transactions as of
18 May 2023
Transactions value $
-$84,930
Form type
4
Filing time
22 May 2023, 18:51:39 UTC
Previous filing
03 Apr 2023
Next filing
09 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLPH Common Stock Options Exercise $1,955 +266 +18.26% $7.35* 1,723 18 May 2023 Direct
transaction BLPH Common Stock Options Exercise $7,665 +1,022 +1.46% $7.5* 1,723 18 May 2023 Direct
transaction BLPH Common Stock Sale -$94,550 -9,455 -84.59% $10* 1,723 18 May 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLPH Stock Options (Right to Buy) Options Exercise $0 -266 -100% $0* 0 18 May 2023 Common Stock 266 $7.35 Direct F2
transaction BLPH Stock Options (Right to Buy) Options Exercise $0 -1,022 -87.65% $0 144 18 May 2023 Common Stock 1,022 $7.5 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.26, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F2 The shares subject to this option are fully vested and exercisable.
F3 This option was granted on September 26, 2019. This option vests in quarterly installments over a four-year period from the date of grant.